TheraRadar
← Back
Data updated: Jun 28, 2026

ACROTECH BIOPHARMA

Specialty
OncologyDermatology Execution: Good

ACROTECH BIOPHARMA is a specialty pharmaceutical company focused on Oncology, Dermatology. Key products include BELEODAQ.

2008
Since
6
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
4 Small Molecules

ACROTECH BIOPHARMA's Key Drugs

ACROTECH BIOPHARMA's core commercial portfolio centers on EVOMELA, BELEODAQ, ADQUEY, spanning Oncology and Dermatology — its most strategically important drugs approved in the last 15 years.

EVOMELA
Oncology

Multiple Myeloma

DNA Approved 2016
BELEODAQ
Oncology

Peripheral T-Cell Lymphoma

HDAC Approved 2014
ADQUEY
Dermatology
Approved 2026

ACROTECH BIOPHARMA's Recent FDA Approvals

ACROTECH BIOPHARMA secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

ADQUEY NDA
2026-02-12
difamilast
1 INDICATIONS & USAGE ADQUEY is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. ADQUEY is a phosphodiesterase 4 inhibitor indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis. (1)

ACROTECH BIOPHARMA's Therapeutic Areas

ACROTECH BIOPHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Dermatology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 85%
3 drugs Phase 3: 1 Phase 2: 5 Phase 1: 12
Dermatology 15%
0 drugs Phase 3: 2

ACROTECH BIOPHARMA's Top Competitors

ACROTECH BIOPHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Dermatology
Baxter specialty
Oncology, Dermatology
Eli Lilly big-pharma
Oncology, Dermatology
Bayer big-pharma
Oncology, Dermatology
KING PHARMS big-pharma
Oncology, Dermatology

ACROTECH BIOPHARMA Pipeline Snapshot

ACROTECH BIOPHARMA has 20 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 5 Phase 2 and 12 Phase 1.

3
Phase 3
5
Phase 2
12
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • EVOMELA leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/3 completed
  • • Speed: 36 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges